Earnings Beat Could Be A Game Changer For Exelixis Stock (EXEL)
Published . Updated .
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Get these market calls by email
The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.
Free. We only use your email to send the digest, never sell or share it, and every email has a one-click unsubscribe link. See our privacy policy.
This report does not map to a usual set of affected companies.
Directly affected
- EXEL Exelixis+27.4% 13d
Named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR holds the health sector that Exelixis belongs to, so it often moves with news about it.
- AMGN Amgen+13.5% 30d
Amgen is a peer of Exelixis in biological products, (no diagnostic substances); rivals often move on the same news.
- GILD Gilead Sciences+13.4% 30d
Gilead Sciences is a peer of Exelixis in biological products, (no diagnostic substances); rivals often move on the same news.
- MRNA Moderna+25.4% 30d
Moderna is a peer of Exelixis in biological products, (no diagnostic substances); rivals often move on the same news.
- ARGX argenx SE-16.8% 15d
argenx SE is a peer of Exelixis in biological products, (no diagnostic substances); rivals often move on the same news.
- RVMD Revolution Medicines
Revolution Medicines is a peer of Exelixis in biological products, (no diagnostic substances); rivals often move on the same news.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| EXEL | -6.18% | -4.45% | base | +1.01% | +4.25% | +2.96% | after close |
| XLV | -3.03% | -2.77% | base | -0.14% | -0.48% | +1.39% | after close |
| AMGN | -4.55% | -3.07% | base | -0.14% | -1.06% | +1.40% | after close |
| GILD | -7.17% | -6.85% | base | -0.33% | -2.02% | +0.53% | after close |
| MRNA | -10.32% | -3.42% | base | -0.33% | +3.06% | +12.06% | after close |
| ARGX | -2.70% | -0.16% | base | -2.03% | +0.94% | +2.05% | after close |
| RVMD | -3.96% | -1.41% | base | -1.67% | +1.47% | +2.14% | after close |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Earnings Beat Could Be A Game Changer For Exelixis Stock (EXEL) Yahoo Finance
Source: Yahoo Finance
This story
| Company | When | Move | Status |
|---|---|---|---|
| AMGN | that day | -0.14% | final price |
| AMGN | the next day | -1.06% | final price |
| AMGN | two days later | +1.40% | still updating |
| AMGN | three days earlier | -3.07% | final price |
| AMGN | five days earlier | -4.55% | final price |
| ARGX | that day | -2.03% | final price |
| ARGX | the next day | +0.94% | final price |
| ARGX | two days later | +2.05% | still updating |
| ARGX | three days earlier | -0.16% | final price |
| ARGX | five days earlier | -2.70% | final price |
| EXEL | that day | +1.01% | final price |
| EXEL | the next day | +4.25% | final price |
| EXEL | two days later | +2.96% | still updating |
| EXEL | three days earlier | -4.45% | final price |
| EXEL | five days earlier | -6.18% | final price |
| GILD | that day | -0.33% | final price |
| GILD | the next day | -2.02% | final price |
| GILD | two days later | +0.53% | still updating |
| GILD | three days earlier | -6.85% | final price |
| GILD | five days earlier | -7.17% | final price |
| MRNA | that day | -0.33% | final price |
| MRNA | the next day | +3.06% | final price |
| MRNA | two days later | +12.06% | still updating |
| MRNA | three days earlier | -3.42% | final price |
| MRNA | five days earlier | -10.32% | final price |
| RVMD | that day | -1.67% | final price |
| RVMD | the next day | +1.47% | final price |
| RVMD | two days later | +2.14% | still updating |
| RVMD | three days earlier | -1.41% | final price |
| RVMD | five days earlier | -3.96% | final price |
| XLV | that day | -0.14% | final price |
| XLV | the next day | -0.48% | final price |
| XLV | two days later | +1.39% | still updating |
| XLV | three days earlier | -2.77% | final price |
| XLV | five days earlier | -3.03% | final price |
Trades by members of Congress and officials in the stocks in this story
- Rep. David J. Taylor bought Amgen (AMGN), worth $1,001 - $15,000 on 22 Sep 2026. That is 39 days before publication. Filed 1 Oct 2026. View the filing.
- Rep. David J. Taylor sold Amgen (AMGN), worth $1,001 - $15,000 on 26 Aug 2026. That is 66 days before publication. Filed 5 Sep 2026. View the filing.
- Sen. Sheldon Whitehouse sold Amgen (AMGN) (held by a spouse), worth $1,001 - $15,000 on 12 Aug 2026. That is 80 days before publication. Filed 2 Sep 2026. View the filing.
- Rep. Rohit Khanna sold Gilead Sciences (GILD) (held by a dependent child), worth $1,001 - $15,000 on 10 Aug 2026. That is 82 days before publication. Filed 4 Sep 2026. View the filing.
- Rep. Maria Elvira Salazar sold Moderna (MRNA), worth $1,001 - $15,000 on 24 Sep 2026. That is 37 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Moderna (MRNA) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 57 days before publication. Filed 7 Oct 2026. View the filing.
- Donald J Trump, an executive branch official, bought Moderna (MRNA), worth $1,001 - $15,000 on 28 Aug 2026. That is 64 days before publication. Filed 8 Oct 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
This story
12 out of 100Price not final
“Earnings Beat Could Be A Game Changer For Exelixis Stock (EXEL)” scores 12 out of 100. The score uses 1 sources. The price is not final yet.